Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an update. Cardiol Therapeutics Inc., a late-stage life sciences company listed on Nasdaq and the T...

Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Cardiol Therapeutics today and set a price target of $9.00. Folkes covers the Hea...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRDL	$1.21	-1.63%	1.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRDL	$1.21	-1.6%	1.42M
3
4
5
6

CRDL

CRDL

Get Cardiol Therapeutics Inc. Data in Excel

Get Cardiol Therapeutics Inc. Data in Excel